He Chenjia, Ren Zhixiang, Xia Xuyang, Xue Zhinan, Zhang Feng, Qian Maoxiang, Shu Yang, Yin Geng, Xie Qibing, Xu Heng
Department of Rheumatology and Immunology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Sci Data. 2025 Jun 10;12(1):977. doi: 10.1038/s41597-025-05339-4.
Although multiple single-cell RNA sequencing (scRNA-seq) based studies have explored rheumatoid arthritis (RA), most have focused on synovial tissue, limiting the ability to perform paired pre- and post-treatment comparisons and to elucidate dynamic changes. Moreover, the single-cell impact of TNF-α and JAK inhibitors on RA remains poorly understood, hindering effects toward precision medicine for RA. Here, we present a comprehensive scRNA-seq analysis of synovial fluid samples of RA patients treated with tofacitinib or adalimumab, both pre- and post-treatment. Following stringent quality control, we analyzed 100,387 high-quality cells, providing an in-depth characterization of cell composition, molecular signaling pathways, and functional properties. This rich dataset offers a valuable resource to address diverse research questions, from uncovering the mechanisms of action of TNF-α and JAK inhibitors, to identifying novel therapeutic targets for RA, and advancing our understanding of the pathogenesis of inflammatory diseases.
尽管多项基于单细胞RNA测序(scRNA-seq)的研究已对类风湿性关节炎(RA)展开探索,但大多数研究都集中在滑膜组织上,这限制了进行治疗前和治疗后配对比较以及阐明动态变化的能力。此外,TNF-α和JAK抑制剂对RA的单细胞影响仍知之甚少,这阻碍了针对RA的精准医学发展。在此,我们展示了对托法替布或阿达木单抗治疗前后的RA患者滑液样本进行的全面scRNA-seq分析。经过严格的质量控制后,我们分析了100387个高质量细胞,对细胞组成、分子信号通路和功能特性进行了深入表征。这个丰富的数据集为解决各种研究问题提供了宝贵资源,从揭示TNF-α和JAK抑制剂的作用机制,到识别RA的新治疗靶点,以及加深我们对炎症性疾病发病机制的理解。